China long-acting bronchodilator market is anticipated to grow at a substantial rate of 3.8% during the forecast period. High level of air pollution and the significant number of smokers in China is boosting the demand for long-acting bronchodilators in the country. Additionally, the rising geriatric population susceptible to asthma and COPD within the country is also driving the demand for bronchodilators. From June 2012 to May 2015, a survey was conducted by the Ministry of Health and Ministry of Science and Technology of China. About 51,000 citizens participated in the survey with 21,500 men and 29,500 women, according to which, it was estimated that about 100 million adults in 2015 had the problem of COPD in the country. The prevalence is higher in men as compared to women. As per the estimation, there were 68.4 million men and 31.5 million women affected by COPD. 

China long-acting bronchodilator market is segmented on the basis of route of administration, application, and end-user. Based on the route of administration, the market is classified into oral, nasal, parenteral, and inhalation. Moreover, on the basis of application, the market has been classified into asthma and COPD diseases. The asthma disease application segment dominated the regional market in 2018 and is further estimated to follow the same trend over the forecast period. This is mainly due to the increasing pool of aging population susceptible to the high prevalence of asthma in the country. 

Furthermore, the market is characterized by the presence of several manufacturers that are developing and providing long-acting bronchodilator to cater to a wide range of customers within and outside the country. The major players of the China long-acting bronchodilator market include Cipla Ltd., AstraZeneca PLC, Beximo Pharmaceuticals Ltd., GlaxoSmithKline PLC, Novartis AG, Teva Pharmaceuticals Industries Ltd., and Teijin Pharma Ltd. These players adopt various strategies to capitalize on market growth opportunities. Mergers and acquisitions, product launch, geographical expansion, partnerships, and collaborations are the majorly adopted strategies by the market players. For instance, in July 2019, Cipla Ltd. announced joint-venture (JV) with China-based Jiangsu Acebright Pharma to make respiratory drugs in China. This JV will allow Cipla to expand its footprints in the country and further strengthen its revenue stream. 

Research Methodology

The market study of the China long-acting bronchodilator market is incorporated by extensive primary and secondary research conducted by the research team. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings the authenticity of our reports.

Secondary Sources Include:

• Financial reports of companies involved in the market
• Whitepapers, research-papers, and news blogs
• Company websites and their product catalog

The report is intended for long-acting bronchodilator manufacturers, contract research organizations (CROs), healthcare sector, market research firms, and government organizations, for overall market analysis and competitive analysis. The report provides an in-depth analysis of the market size and growth opportunities. The report will serve as a source for 360-degree analysis of the market thoroughly delivering insights into the market for making better business decisions.

Market Segmentation:

1. China Long-Acting Bronchodilator Market Research and Analysis by Route of Administration

2. China Long-Acting Bronchodilator Market Research and Analysis by Application

3. China Long-Acting Bronchodilator Market Research and Analysis by End-User

The Report covers:

• Comprehensive research methodology of the China long-acting bronchodilator market.
• This report also includes a detailed and extensive market overview with key analyst insights.
• An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
• Analysis of regional regulations and other government policies impacting the China long-acting bronchodilator market.
• Insights about market determinants which are stimulating the China long-acting bronchodilator market.
• Detailed and extensive market segments with regional distribution of forecasted revenues.
• Extensive profiles and recent developments of market players.